prikaz prve stranice dokumenta Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
  Download
PDF 704.41 KB
Scientific paper - Review paper
Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
World Journal of Transplantation, 11 (2021), 3; 37-53. https://doi.org/10.5500/wjt.v11.i3.37
Mikolašević, Ivana; Stojsavljević, Sanja; Blažić, Filip; Mijić, Maja; Radić-Kristo, Delfa; Jurić, Toni; Skenderević, Nadija; Klapan, Mia; Lukić, Andjela; Filipec Kanižaj, Tajana

Cite this document

Mikolašević, I., Stojsavljević, S., Blažić, F., Mijić, M., Radić Kristo, D., Jurić, T. ... Filipec Kanižaj, T. (2021). Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?. World Journal of Transplantation, 11. (3), 37-53. doi: 10.5500/wjt.v11.i3.37

Mikolašević, Ivana, et al. "Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?." World Journal of Transplantation, vol. 11, no. 3, 2021, pp. 37-53. https://doi.org/10.5500/wjt.v11.i3.37

Mikolašević, Ivana, Sanja Stojsavljević, Filip Blažić, Maja Mijić, Delfa Radić Kristo, Toni Jurić, Nadija Skenderević, Mia Klapan, Andjela Lukić and Tajana Filipec Kanižaj. "Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?." World Journal of Transplantation 11, no. 3 (2021): 37-53. https://doi.org/10.5500/wjt.v11.i3.37

Mikolašević, I., et al. (2021) 'Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?', World Journal of Transplantation, 11(3), pp. 37-53. doi: 10.5500/wjt.v11.i3.37

Mikolašević I, Stojsavljević S, Blažić F, Mijić M, Radić Kristo D, Jurić T, and sur.. Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?. World Journal of Transplantation [Internet]. 2021 March 18 [cited 2024 August 21];11(3):37-53. doi: 10.5500/wjt.v11.i3.37

I. Mikolašević, et al., "Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?", World Journal of Transplantation, vol. 11, no. 3, pp. 37-53, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:822966. [Accessed: 21 August 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
AuthorIvana Mikolašević
AuthorSanja Stojsavljević
AuthorFilip Blažić
AuthorMaja Mijić
AuthorDelfa Radić-Kristo
AuthorToni Jurić
AuthorNadija Skenderević
AuthorMia Klapan
AuthorAndjela Lukić
AuthorTajana Filipec Kanižaj
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
In the last two decades, advances in immunosuppressive regimens have led to fewer complications of acute rejection crisis and consequently improved short-term graft and patient survival. In parallel with this great success, long-term post-transplantation complications have become a focus of interest of doctors engaged in transplant medicine. Metabolic syndrome (MetS) and its individual components, namely, obesity, dyslipidemia, diabetes, and hypertension, often develop in the post-transplant setting and are associated with immuno-suppressive therapy. Nonalcoholic fatty liver disease (NAFLD) is closely related to MetS and its individual components and is the liver manifestation of MetS. Therefore, it is not surprising that MetS and its individual components are associated with recurrent or "de novo" NAFLD after liver transplantation (LT). Fibrosis of the graft is one of the main determinants of overall morbidity and mortality in the post-LT period. In the assessment of post-LT steatosis and fibrosis, we have biochemical markers, imaging methods and liver biopsy. Because of the significant economic burden of post-LT steatosis and fibrosis and its potential consequences, there is an unmet need for noninvasive methods that are efficient and cost-effective. Biochemical scores can overestimate fibrosis and are not a good method for fibrosis evaluation in liver transplant recipients due to frequent post-LT thrombocytopenia. Transient elastography with controlled attenuation parameter is a promising noninvasive method for steatosis and fibrosis. In this review, we will specifically focus on the evaluation of steatosis and fibrosis in the post-LT setting in the context of de novo or recurrent NAFLD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleWorld Journal of Transplantation
Numberingvol. 11, no. 3, pp. 37-53
p-ISSN2220-3230
DOIhttps://doi.org/10.5500/wjt.v11.i3.37
URN:NBNurn:nbn:hr:184:822966
Publication2021-03-18
Document URLhttps://www.wjgnet.com/2220-3230/full/v11/i3/37.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2021-04-13 16:55:55